The NeuraMetrix solution provides Biopharmaceutical companies with a much more precise, accurate, and cost-effective Digital Cognitive Biomarker for Clinical Drug Development
The gap
The main issues for drug trials within neurological diseases and psychiatric disorders today are:
Difficult to successfully develop new drugs when the cohort is based on patients where the disease has already progressed beyond where the drugs can have an impact
No ability to monitor "in real-time" the effect on each trial participant
Difficult to measure cognitive side effects of their drugs
Do not have an early warning system if the drug is not functioning
NeuraMetrix' highly precise and easy to implement digital biomarker fills an important gap long sought after by the biotech and pharmaceutical industry
With the NeuraMetrix digital biomarker drug trials for neurological diseases and psychiatric disorders can:
Remove any patients from the cohort where the disease has already progressed beyond where the drugs can have an impact
Ability to monitor "in real-time" what the effect is for each trial participant
Measure cognitive side effects of their drugs
Get an early warning if the drug is not functioning
This enables biotech and pharmaceutical companies to:
NeuraMetrix is a San Francisco based Medical Device company. It offers a novel, unique, highly accurate digital biomarker to detect and monitor a range of Neurological diseases and Psychiatric disorders.
